A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
Latest Information Update: 13 Jan 2025
At a glance
- Drugs Abemaciclib (Primary) ; Loperamide; Tamoxifen
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms nextMONARCH 1
- Sponsors Eli Lilly and Company
Most Recent Events
- 09 Jan 2025 Planned End Date changed from 30 Dec 2024 to 1 Dec 2025.
- 27 Oct 2023 Results deriving baseline and end-of-treatment plasma samples from patients in MONARCH 3 and nextMONARCH (monotherapy arms) to identify somatic genomic alterations, lished in the Clinical Cancer Research
- 11 Sep 2023 Planned End Date changed from 20 Sep 2023 to 30 Dec 2024.